Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell MalignanciesJOURNAL OF MEDICINAL CHEMISTRYIF6.82024-02-0121OA
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127ScienceIF45.82024-01-010OA
NX-2127: A first-inclass clinical stage degrader of BTK and IKZF1/3 for the treatment of patients with B cell malignanciesCANCER RESEARCHIF16.62023-04-044PRE
NX-5948 promotes selective, sub-nanomolar degradation of inhibitor-resistant BTK mutantsCANCER RESEARCHIF16.62023-04-042PRE
NR4A nuclear receptors restrain B cell responses to antigen when second signals are absent or limitingNATURE IMMUNOLOGYIF27.62020-08-3150OAAI
Self-reactivity on a spectrum: A sliding scale of peripheral B cell toleranceIMMUNOLOGICAL REVIEWSIF8.32019-10-2035OAAI
Optimal Development of Mature B Cells Requires Recognition of Endogenous AntigensJOURNAL OF IMMUNOLOGYIF3.42019-07-1517OAAI
Nur77 Links Chronic Antigen Stimulation to B Cell Tolerance by Restricting the Survival of Self-Reactive B Cells in the PeripheryJOURNAL OF IMMUNOLOGYIF3.42019-05-1532OAAI
Control of autoreactive B cells by IgM and IgD B cell receptors: maintaining a fine balanceCURRENT OPINION IN IMMUNOLOGYIF5.82018-12-0120OAAI
IgM and IgD B cell receptors differentially respond to endogenous antigens and control B cell fateELIFEIF02018-03-0975OAAI
An extracatalytic function of CD45 in B cells is mediated by CD22B细胞中CD45的体外催化功能由CD22介导PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAIF9.12015-11-1131OA
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向